Business Wire

CO-ANANDA-SCIENTIFIC

8.6.2021 13:02:05 CEST | Business Wire | Press release

Share
ANANDA Scientific and NYU Grossman School of Medicine Announce First Patient Enrolled in the Clinical Trial Evaluating Liquid Structure™ Cannabidiol (CBD) for Treatment of Post-Traumatic Stress Disorder (PTSD)

ANANDA Scientific Inc. , a biotech pharmaceutical company, and NYU Grossman School of Medicine today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S , an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology as a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms and Neurocognitive Impairment in patients with PTSD and with PTSD comorbid with Traumatic Brain Injury (TBI).

“This is an important milestone for ANANDA’s clinical development program, and we look forward to continuing to work with the NYU Grossman School of Medicine. We are impressed by the scientific rigor and professionalism of the NYU team in getting a cutting-edge program in place to test the efficacy of our very promising drug,” said Sohail R. Zaidi, ANANDA’s President . “The initiation of patient enrollment in this study reinforces our commitment to our goal of improving Health and Wellness empowered by cannabinoid science. This is also an important step in our efforts to provide patients with PTSD with potentially improved therapeutic options.”

This trial is being conducted at NYU Grossman School of Medicine, led by Esther Blessing, MD PhD , Assistant Professor of Psychiatry, and Charles R. Marmar, MD, the Lucius N. Littauer Professor and Chair of Psychiatry. Dr. Marmar, leader of the NYU Langone PTSD Research Program, is the primary investigator of several personalized medicine-based clinical trials of innovative treatments for PTSD and its common comorbidities, using cutting-edge biomarker technologies to understand mechanisms underlying treatment effects.

“We are excited to get this important trial underway. Our collaboration with ANANDA Scientific allows us to progress in the development of evidence-based CBD products for this debilitating condition,” said Dr. Marmar.

The Phase II study is an eight week, double-blind, randomized, placebo controlled study with adaptive dose design evaluating the effect of Nantheia™ A1002N5S on PTSD symptoms and neurocognitive function in 120 patients with PTSD, 50% with comorbid mild TBI. (ClinicalTrials.gov Identifier: NCT04550377 )

ABOUT NANTHEIA™ A1002N5S

Nantheia™ A1002N5S is an investigational drug being evaluated for the treatment of PTSD. The drug uses CBD in ANANDA’s propriety delivery technology. Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure delivery technology (licensed from Lyotropic Delivery Systems (LDS) Ltd. in Jerusalem, Israel) enhances the effectiveness and stability of CBD. Nantheia™ A1002N5S is an oral product with 50 mg CBD per softgel capsule.

ABOUT PTSD

PTSD, a relatively common disorder that may develop following a traumatic event, has a US lifetime prevalence of 1.3–12.2%, with higher rates (12–20%) in individuals exposed to military combat [1, 2] [3]. Disabling symptoms include intrusive memories of the event, avoidance of reminders, negative cognitions and hyperarousal. In addition, PTSD is associated with neurocognitive impairment, which interacts to worsen PTSD symptoms and impair treatment outcomes [4] [5-7] [8, 9]. Traumatic brain injury (TBI), experienced by up to 35% of veterans returning from the OEF/OIF conflicts [10], is often comorbid with PTSD and increases the risk of PTSD by up to 3-fold [11-14]. TBI history is an important factor in PTSD treatment development: even mild TBI can lead to long-term neurocognitive impairment, as well as persistent post concussive symptoms – many of which are common to PTSD symptoms [12, 14-16]. Current pharmacotherapies, largely repurposed from other indications, do not reliably improve PTSD symptoms or associated neurocognitive impairment in PTSD or TBI [17-19]. Novel, targeted medications that treat these overlapping symptoms in a coordinated simultaneous fashion are urgently needed.

ABOUT ANANDA SCIENTIFIC (www.anandascientific.com )

ANANDA is a leading research-focused biotech company pioneering high-caliber clinical studies evaluating therapeutic targets for cannabinoids. The company employs patented delivery technologies to make cannabinoids and other plant derived compounds highly bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium quality nutraceutical and pharmaceutical products. Consistent with its strong research-based data, the company also has a growing pipeline of nutraceutical over-the-counter products. The company has successfully launched these products in the US and the UK, with expansion into additional markets such as the EU, China, Australia and Africa planned for the near future. The company is expanding its research base through multiple sponsored research agreements with universities to diversify its technology portfolio.

REFERENCES

  1. Kessler, R.C., et al., Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 2005. 62 (6): p. 593-602.
  2. Hoge, C.W., et al., Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med, 2004. 351 (1): p. 13-22.
  3. Shalev, A., I. Liberzon, and C. Marmar, Post-Traumatic Stress Disorder. N Engl J Med, 2017. 376 (25): p. 2459-2469.
  4. Hayes, J.P., M.B. Vanelzakker, and L.M. Shin, Emotion and cognition interactions in PTSD: a review of neurocognitive and neuroimaging studies. Front Integr Neurosci, 2012. 6 : p. 89.
  5. Haaland, K.Y., et al., Neurocognitive Correlates of Successful Treatment of PTSD in Female Veterans. J Int Neuropsychol Soc, 2016. 22 (6): p. 643-51.
  6. Aupperle, R.L., et al., Dorsolateral prefrontal cortex activation during emotional anticipation and neuropsychological performance in posttraumatic stress disorder. Arch Gen Psychiatry, 2012. 69 (4): p. 360-71.
  7. Aupperle, R.L., et al., Executive function and PTSD: disengaging from trauma. Neuropharmacology, 2012. 62 (2): p. 686-94.
  8. Nijdam, M.J., et al., Neurocognitive functioning over the course of trauma-focused psychotherapy for PTSD: Changes in verbal memory and executive functioning. Br J Clin Psychol, 2018.
  9. Morey, R.A., et al., Neural systems for executive and emotional processing are modulated by symptoms of posttraumatic stress disorder in Iraq War veterans. Psychiatry Res, 2008. 162 (1): p. 59-72.
  10. Rigg, J.L. and S.R. Mooney, Concussions and the military: issues specific to service members. PM R, 2011. 3 (10 Suppl 2): p. S380-6.
  11. Langlois, J.A., W. Rutland-Brown, and M.M. Wald, The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil, 2006. 21 (5): p. 375-8.
  12. Stein, M.B. and T.W. McAllister, Exploring the convergence of posttraumatic stress disorder and mild traumatic brain injury. Am J Psychiatry, 2009. 166 (7): p. 768-76.
  13. Tanev, K.S., et al., PTSD and TBI co-morbidity: scope, clinical presentation and treatment options. Brain Inj, 2014. 28 (3): p. 261-70.
  14. Kaplan, G.B., et al., Pathophysiological Bases of Comorbidity: Traumatic Brain Injury and Post-Traumatic Stress Disorder. J Neurotrauma, 2018. 35 (2): p. 210-225.

Link:

ClickThru

Social Media:

https://facebook.com/anandascientific

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SatSure Raises Series B to Scale Its Full-Stack Earth Intelligence Platform for Global Markets20.11.2026 11:05:00 CET | Press release

India’s sovereign space-technology fund leads the first close of the ongoing INR 200 crore (c. USD 21 million) round SatSure, a global Earth intelligence company headquartered in India, today announced the first close of its ongoing INR 200 crore (c. USD 21 million) Series B round. The round is led by a INR 60 crore (c. USD 6.4 million) investment from the Antariksh Venture Capital Fund (AVCF), India’s sovereign space-technology fund, anchored by the national space regulator IN-SPACe and managed by SIDBI Venture Capital Limited. The investment marks AVCF’s first deployment into the downstream data and AI layer of India’s space economy, extending the fund beyond upstream launch and satellite hardware into commercial space-data infrastructure capable of serving global enterprise and sovereign markets. The round comprises INR 165 crore (c. USD 17.6 million) in equity, INR 25 crore (c. USD 2.7 million) in venture debt and INR 10 crore (c. USD 1.1 million) in secondary transactions, closing

Al Shera’a, DEWA’s Headquarters, Wins First Place in the YeS Honor Awards at the COP31 International Sustainable Buildings Competition20.11.2026 10:16:00 CET | Press release

In a new achievement that underscores Dubai’s pioneering position in smart and sustainable buildings, Al Shera’a, the headquarters of Dubai Electricity and Water Authority (DEWA), has won the first place in the YeS Honor Award–Sustainable Design category, in the COP31 International Sustainable Buildings Competition. The award was launched by the COP31 Presidency with the support of the Global Alliance for Buildings and Construction, hosted by the United Nations Environment Programme, during COP31 in Antalya, Türkiye. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118255551/en/ HE Saeed Mohammed Al Tayer, MD&CEO of DEWA, received the award in the presence of HE Amna bint Abdullah Al Dahak, UAE Minister of Climate Change and Environment, from HE Hasan Suver, Deputy Minister of Environment, Urbanisation and Climate Change of the Republic of Türkiye, representing the COP31 Presidency. The competition attracted more than 1,000

teamLab Biovortex Kyoto to Open 'Teahouse in a Sea of Light' for Savoring Tea. On View from Friday, November 20. Artworks Including Tea in Spontaneous Order on View20.11.2026 07:00:00 CET | Press release

teamLab Biovortex Kyoto opens ‘Teahouse in a Sea of Light’ on Friday, November 20, 2026, where visitors can savor tea within the Sea of Solidified Light. Artworks exhibited in the teahouse, including Tea in Spontaneous Order, are now unveiled. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117922442/en/ Aged Coffee Tonic, Tea in Spontaneous Order, 2021- ©︎ teamLab *Shot in real space. No AI or CGI. *No Artificial Colors Teahouse in a Sea of Light A space for savoring tea within a sea of light. When a cup of tea is made, the artwork is born. The tea interacts with nearby tea and the sea of light, creating a time structure throughout the entire space of the artwork. Visitors drink part of this formed order itself. Coinciding with the opening of ‘Teahouse in a Sea of Light,’ Pocket Garden of Eternal Existence is newly unveiled at the museum's entrance gate. teamLab Biovortex Kyoto teamLab Biovortex Kyoto is teamLab's largest

OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac

ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release

Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye